High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.
about
Pseudomonas aeruginosa biofilms in cystic fibrosisCefepime-aztreonam: a unique double beta-lactam combination for Pseudomonas aeruginosa.Efficacy of 1% acetic acid in the treatment of chronic wounds infected with Pseudomonas aeruginosa: prospective randomised controlled clinical trial.Structural and functional characterization of Pseudomonas aeruginosa global regulator AmpR.The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria.Pseudomonas biofilm matrix composition and niche biologyDevelopment and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patientsPotential biomarkers associated with diabetic glomerulopathy through proteomics.Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry.Characterization of a Carbapenem-Hydrolyzing Enzyme, PoxB, in Pseudomonas aeruginosa PAO1.Pseudomonas aeruginosa biofilms exposed to imipenem exhibit changes in global gene expression and beta-lactamase and alginate production.Efflux unbalance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections.Pseudomonas aeruginosa Diversification during Infection Development in Cystic Fibrosis Lungs-A Review.Pseudomonas aeruginosa AmpR is a global transcriptional factor that regulates expression of AmpC and PoxB beta-lactamases, proteases, quorum sensing, and other virulence factors.Antibodies against chromosomal beta-lactamase.Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilmsComparison of methods to test antibiotic combinations against heterogeneous populations of multiresistant Pseudomonas aeruginosa from patients with acute infective exacerbations in cystic fibrosis.Outer membrane vesicles shield Moraxella catarrhalis β-lactamase from neutralization by serum IgG.Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection.Regulation of Class A β-Lactamase CzoA by CzoR and IscR in Comamonas testosteroni S44.Contribution of the MexAB-OprM multidrug efflux system to the beta-lactam resistance of penicillin-binding protein and beta-lactamase-derepressed mutants of Pseudomonas aeruginosa.Detection of Bacteriophage Particles Containing Antibiotic Resistance Genes in the Sputum of Cystic Fibrosis Patients.
P2860
Q28299966-A93769F3-C4E6-4FF7-9C17-CEB9B35ACE14Q33693985-813B0D3D-ACF2-4040-BE5F-EFC285F76EACQ34470695-00E8AD89-19D3-4F18-9BB4-D99471555612Q34593307-A9F525A0-9DDE-43B8-A579-D451B7D60A09Q35482558-62A7871A-558B-407A-8C78-14D1B18441C8Q35538261-26CA94D7-6EB8-4AB1-9A7A-03B2FDF15FCCQ35758992-041385FF-B30F-4C3B-91BD-79C1F204508CQ35771804-A57F614E-97BC-473B-BB1F-FCC397F47469Q36496456-69036432-0317-44F3-89B0-CC51BEAD42BAQ36571851-11E43D4D-0F00-4A9A-90C4-7E61DBE087BBQ37119379-8117B5CA-84E7-4B0F-AFAF-0F3984B8677CQ37190771-542D491B-77A3-4F72-98CF-B7BDC8670645Q38006032-A05BFE6A-7A4E-44ED-A424-3986FAF1333DQ38273318-99F575B9-B585-441E-AA8E-75E710B5345FQ39609127-B4A67903-2170-464E-A0FA-1A93ED9596A0Q40286585-9DF15C6D-1984-4DA5-ACF8-2F5B84D7DE34Q40705879-250A02A6-B853-4CC7-BEEF-BE1102997121Q42612276-4990E2D5-A4E0-4FDD-B664-46AE49D829CFQ43435961-8E75EFEA-C555-4CE2-A9E8-77E8B5A92181Q44367885-EAE8D7CA-9E58-4FE7-95D1-457C4EE0D223Q47192196-C10E512B-23B1-4737-BAC8-FA110630CBD2Q54070064-6803AAB6-CBE8-4740-B862-5A1E3B1B634AQ55373289-2AD76A8A-5216-4F39-A333-75F0B0AD96E8
P2860
High-level beta-lactamase activity in sputum samples from cystic fibrosis patients during antipseudomonal treatment.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
High-level beta-lactamase acti ...... ing antipseudomonal treatment.
@ast
High-level beta-lactamase acti ...... ing antipseudomonal treatment.
@en
type
label
High-level beta-lactamase acti ...... ing antipseudomonal treatment.
@ast
High-level beta-lactamase acti ...... ing antipseudomonal treatment.
@en
prefLabel
High-level beta-lactamase acti ...... ing antipseudomonal treatment.
@ast
High-level beta-lactamase acti ...... ing antipseudomonal treatment.
@en
P2093
P2860
P356
P1476
High-level beta-lactamase acti ...... ing antipseudomonal treatment.
@en
P2093
P2860
P356
10.1128/AAC.36.1.71
P407
P577
1992-01-01T00:00:00Z